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thickness in diabetic patients.6 Also, microangi‑
opathic complications in patients with T2DM are 
associated with carotid plaque score.7 Therefore, 
diabetes therapy, oriented not only at normaliz‑
ing blood sugar, but also at minimizing the risk 
of CV events, must be multifactorial and requires 
cooperation of a diabetologist, cardiologist, ne‑
phrologist, and physicians of other specialties.8
This paper presents the current state of knowl‑
edge on the  impact of glycemic disorders on 
the CV system and new mechanisms that have 
been developed recently to correct glucometabol‑
ic disturbances in patients with high CV risk. In 
addition, based on the results of recent clinical 
trials and reviews of studies and meta ‑analyses, 
an attempt was made to answer the question of 
whether glycemic control affects the survival of 
patients with diabetes and CV risk, which seems 
important from the practitioner’s point of view.
Postprandial hyperglycemia The influence of post‑
prandial glycemia on the development of diabe‑
tes complications has been consistently neglect‑
ed for many years. The commonly used glycemic 
Introduction Diabetes is one of the most com‑
mon diseases in the world. It is estimated to oc‑
cur in 382 million people, and the number of pa‑
tients may increase to 592 million by 2035.1 Ac‑
cording to the World Health Organization data, in 
2012, 1.5 million deaths were related to this dis‑
ease.2 The main cause of morbidity and mortali‑
ty among diabetic patients is cardiovascular dis‑
ease (CVD), including atherosclerosis and its clin‑
ical consequences (coronary heart disease, myo‑
cardial infarction [MI], and stroke). Compared 
with patients without diabetes patients, diabet‑
ic individuals have twice the relative risk of car‑
diovascular (CV) death.3
CV complications in diabetes are associated 
with hyperglycemia and other glycemic abnormal‑
ities.4 Moreover, the increased risk of macrovas‑
cular atherosclerosis ‑based complications in pa‑
tients with type 2 diabetes (T2DM) is associated 
with the presence of chronic inflammation, dys‑
lipidemia, hypertension, and accompanying dis‑
eases and depends on the duration of diabetes 
and age of the patient.5 Increased cardio metabolic 
risk is also associated with higher epicardial fat 
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ABSTRACT
Diabetes increases the risk of cardiovascular (CV) diseases, which are the leading cause of mortality 
among diabetic patients. Although hyperglycemia is a major determinant of macrovascular and micro­
vascular complications in diabetes, hypoglycemia and glycemic variability have also a strong influence 
on the cardiovascular system. This overview presents the current state of knowledge on the impact of 
type 2 diabetes on the CV system and new therapeutic strategies that have been recently developed 
to correct gluco se metabolism disorders in patients with high CV risk, such as glucagon ­like peptide 
1 receptor agonists, dipeptidyl peptidase ­4 inhibitors, and sodium–glucose cotransporter ­2 inhibitors. 
Results of several large randomized clinical trials (such as EMPA ­REG, LEADER, SUSTAIN ­6, and CAN­
VAS) assessing the efficacy and safety of drugs based on new mechanisms deserve attention due to 
their beneficial effect on serious CV events, including CV death, myocardial infarction, and stroke. In 
addition, based on the results of recent studies and meta ­analyses, an attempt was made to answer 
the questions of whether the actions of new drugs are mediated solely by the glucose ­lowering effect 
and whether indeed glycemic control affects the survival of patients with diabetes and CV risk, which 
seems of key importance from the clinical perspective. 
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found to be significant predictors of the CVD in‑
cidence and general mortality, after adjusting 
for the number of measurements, mean HbA1c 
levels, age, sex, and other classic CVD risk fac‑
tors. The study concluded that postprandial hy‑
perglycemia noted at clinic visits was associated 
with CVD incidence and all ‑cause overall mortal‑
ity independently of the mean HbA1c level in pa‑
tients with T2DM.
Additional evidence for the relationship of 
postprandial glucose with CV risk was provided 
by a meta ‑analysis of 20 prospective studies, in‑
cluding a total of 95 783 patients,with a follow‑
‑up of 12.4 years, which showed a significant as‑
sociation between CV risk and glycemia 2 hours 
post ‑load.20 The authors also emphasized that 
the progressive relationship between glucose con‑
centrations and CV risk occurs below the level of 
glycemia determining the diagnosis of diabetes.
In addition to postprandial hyperglycemia, 
the role of postprandial lipotoxicity is increas‑
ingly underlined as an important mechanism 
in the pathogenesis of CVD. Many studies have 
shown that postprandial increases in triglyceride 
levels and postprandial glycemia in an indepen‑
dent and additive manner adversely affect endo‑
thelial function and increase inflammation.13,21 
There is ample evidence to support the hypothe‑
sis that hyperglycemia and hypertriglyceridemia 
are proatherogenic mainly due to intensification 
of oxidative stress.22
In the context of the results of the above stud‑
ies indicating a significant contribution of post‑
prandial glucose to CV risk, the question aris‑
es as to whether therapeutic interventions spe‑
cifically targeted at postprandial glucose control 
have an impact on the reduction of the number 
of CV events. Unfortunately, there are no inter‑
ventional studies with major adverse CV events 
as the endpoints that would provide evidence 
that postprandial glucose correction will trans‑
late into benefits in terms of lowering CV risk.
In a small study of 23 patients with T2DM and 
10 healthy subjects, postprandial hyperglycemia 
in diabetic patients was shown to influence endo‑
thelial function assessed by ultrasound measure‑
ment of flow ‑mediated dilation (FMD) of the bra‑
chial artery and that the fast ‑acting insulin ana‑
logue (insulin aspart) improves endothelial func‑
tion by reducing postprandial hyperglycemia.23
A randomized trial that compared the inten‑
sive insulin therapy with fast‑ and long ‑acting 
insulin analogues in the multiple daily injection 
algorithm with standard therapy with human 
insulin (with intermediate action time—neu‑
tral protamine Hagedorn and regular)24 showed 
that in 109 patients with T2DM (61 in the insu‑
lin analogue group and 48 in the human insulin 
group) in whom it was sought to achieve fast‑
ing blood glucose of 110 mg/dl or less and post‑
prandial glycemia of 150 mg/dl or less, no differ‑
ences were found in fasting blood glucose levels 
at 36 months of follow ‑up. Using the Doppler 
method, a reduction in the diastolic dysfunction 
parameters, such as fasting glucose and glycosyl‑
ated hemoglobin A1c (HbA1c) levels, do not include 
short ‑term but significant increases in glucose 
levels after meals (hyperglycemia spikes). More‑
over, neither fasting glucose nor HbA1c was able 
to fully explain the effect of glycemic abnormal‑
ities on CV risk in patients with diabetes. Con‑
trary to what was previously expected, the rela‑
tionship between macroangiopathy and fasting 
glycemia or HbA1c levels was found to be weak‑
er than that observed in the case of microangio‑
pathic complications.9 More attention was there‑
fore paid to the impact of postprandial glucose.
Experimental and clinical studies have also 
demonstrated short ‑term and long ‑term effects of 
postprandial glycemia on the function of the vas‑
cular endothelium in both healthy and diabet‑
ic patients.10-12 Glycemic spikes occurring after 
a meal may cause impairment of nitric oxide‑
‑dependent endothelial functions, activation of 
blood coagulation, increase of adhesin produc‑
tion, and enhanced oxidative stress.13 The rela‑
tionship between postprandial hyperglycemia 
and the intima ‑media thickness, an early mark‑
er of CVD, has been demonstrated.14
The relationship between high glucose levels af‑
ter a meal and the risk of CV events has been doc‑
umented in epidemiological studies.15-17 Results 
obtained by the DECODE research group,15 evalu‑
ated fasting blood glucose and blood glucose levels 
2 hours after oral loading of 75 g glucose (equiv‑
alent to postprandial glycemia). It was based on 
data from 13 European prospective cohort stud‑
ies including a total of 25 364 people, at least 
30 years of age, and with an average follow ‑up 
of 7.3 years.15 The analysis clearly showed that 
the increase in glycemia in the second hour after 
loading is a stronger risk factor for CV death and 
independent of fasting blood glucose.
Cavalot et al18 observed 505 consecutive pa‑
tients with T2DM for the follow ‑up period of 
14 years. At baseline, patients were assessed for 
classic CVD risk factors and 5 glycemic parame‑
ters (including blood glucose 2 hours after break‑
fast and after lunch). A total of 172 CVD events 
and 147 deaths were reported. It was observed 
that both postprandial blood glucose (measured 
2 hours after lunch) and HbA1c levels predict‑
ed CVD occurrence and general mortality also 
when taking into account classic nonglycemic 
CVD risks. The results of the post ‑breakfast tests 
were less representative due to the low ‑calorie 
breakfast composition (cup of coffee, sometimes 
with a small piece of bread) at the time of study 
initiation.
A recent retrospective observational real ‑world 
cohort study on 646 patients with T2DM was 
conducted to examine the impact of postprandi‑
al hyperglycemia independently of mean HbA1c 
levels.19 During the mean follow ‑up period of ap‑
proximately 16 years, CVD affected 78 of 618 pa‑
tients with no CVD history reported at first vis‑
it, and 56 of all 646 patients died. The mean val‑
ues of blood glucose 2 hours post breakfast were 
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Glucose variability was expressed as the MAGE 
index. A significant correlation was found be‑
tween MAGE and the volume of the necrotic core 
in the atherosclerotic plaque. Moreover, MAGE 
was the only independent predictor of the occur‑
rence of thin ‑cap fibroatheroma—the so called 
vulnerable plaque characterized by a high risk of 
rupture. The results of this study might suggest 
that daily glycemic variability can affect the vul‑
nerability of the atherosclerotic plaque in pa‑
tients with coronary artery disease during lipid‑
‑lowering treatment. Therefore, avoiding glyce‑
mic variability may be a therapeutic goal equiva‑
lent to the control of dyslipidemia, and contribute 
to a reduction in the incidence of acute coronary 
syndromes, the most frequent cause being ath‑
erosclerotic plaque rupture.
In another recent study by Constantino et al,32 
glycemic variability (MAGE and postprandial 
incremental area under the curve) in patients 
achieving target HbA1c levels (≤7.0%) was ob‑
served to alter the epigenetic regulatory profile 
on the p66Shc promoter (a key protein of the mi‑
tochondrial oxidative stress process). Patients 
were introduced on an intensive glycemic con‑
trol for 6 months; however, it did not change ad‑
verse epigenetic remodeling (DNA hypomethyl‑
ation and histone 3 acetylation on the p66Shc pro‑
moter) as well as impaired FMD and increased 
urinary 8 ‑isoPGF2α levels. Therefore, the study 
proved that glucose variability might influence 
the epigenetic mechanisms of sustained chromat‑
ic remodeling in patients with T2DM achieving 
target HbA1c levels and lead to CV complications.
Hypoglycemia Numerous epidemiological studies 
have shown a relationship between hypoglycemia 
and an increased risk of CV death.33-35 The harm‑
ful effect of severe symptomatic hypoglycemia, 
which may lead to myocardial ischemia,36 life‑
‑threatening cardiac arrhythmia, and sudden 
cardiac death,37 is particularly well documented. 
Recent studies have suggested that asymptom‑
atic hypoglycemia and even low blood glucose 
levels,not yet meeting the criterion of hypogly‑
cemia, may also have a negative impact on the CV 
system by adversely influencing endothelial func‑
tion, weakening of endothelium ‑dependent vaso‑
dilation, enhancement of oxidative stress and in‑
flammation, and promotion of the prothrombot‑
ic state as well as a direct impact on the myocar‑
dium by increasing the catecholamine outburst, 
enhancing adrenergic stimulation, and reducing 
the coronary reserve.38,39 In clinical practice, in‑
creasing attention is being paid to patients who 
do not feel symptoms of hypoglycemia and who 
show an increase in thrombin generation and 
platelet activity.40
In an observational study, Chow et al41 used 
continuous glucose monitoring (CGM) and 
24 ‑hour Holter monitoring in 25 patients with 
T2DM treated with insulin, with CVD or 2CV 
risk factors. Hypoglycemia has been shown to be 
a frequent phenomenon in these patients—it was 
was shown in the group where postprandial gly‑
cemia was more effectively controlled.
One of the larger studies that focused on post‑
prandial hyperglycemia spike control was the ran‑
domized STOP ‑NIDDM.25 A total of 1429 patients 
with impaired glucose tolerance were enrolled to 
2 groups: treated with acarbose (a drug ‑reducing 
postprandial hyperglycemia, 714 individuals) and 
placebo (715 individuals). The effectiveness of 
acarbose in the prevention of diabetes and reduc‑
tion in the risk of CVD was assessed. After an av‑
erage follow ‑up of 3.3 years, the acarbose group 
showed a 49% reduction in the risk of CV events 
compared with placebo, in addition to a 25% re‑
duction in the risk of developing T2DM.
Glycemic variability Glycemic variability is anoth‑
er element in the care of diabetic patients, which 
has recently attracted the attention of diabetol‑
ogists and cardiologists. Analysis of the results 
of the frequently cited DCCT (Diabetes Control 
and Complications Trial) showed that patients 
treated more intensively had a significantly low‑
er risk of microangiopathic complications com‑
pared with patients treated as standard, although 
the HbA1c level in both groups was comparable.
26 
Therefore, it was suggested that there must be an‑
other independent factor that determines the risk 
of developing long ‑term complications of diabe‑
tes on top of glycemic control expressed by HbA1c. 
It was suggested that the frequency and ampli‑
tude of glycemic variability could be this factor. 
Numerous studies conducted in vitro and on an‑
imal model have shown a causal relationship be‑
tween the variability in glucose levels over time 
and abnormalities in endothelial function.27-29 
These observations have also been confirmed in 
studies conducted in humans.
One of such studies was conducted by Ceri‑
ello et al,30 who used the hyperglycemic clamp 
method in patients with T2DM and healthy sub‑
jects. Participants were subjected to constant or 
variable glucose concentrations within 24 hours, 
followed by the assessment of endothelial func‑
tion (by FMD) and oxidative stress marker (plas‑
ma levels of nitrotyrosin and urinary levels of 
8 ‑iso ‑PGF2α). The authors showed that glyce‑
mic variability over time exacerbates endotheli‑
al dysfunction to a greater degree than constant‑
ly high glucose levels, and that oxidative stress 
plays a key role in this phenomenon.
In another recent study, the determinants of 
autonomic neuropathy of the CV system were 
evaluated depending on the degree of glycemic 
control in patients with newly diagnosed T2DM.31 
It was observed that glycemic variability ex‑
pressed by the mean amplitude of glycemic ex‑
cursions (MAGE) index was the only factor show‑
ing an independent association with the pres‑
ence of autonomic neuropathy of the CV system.
Recently, the effect of daily glycemic changes 
on atherosclerotic plaque morphology was as‑
sessed in patients with coronary artery disease 
using virtual histology intravascular ultrasound.17 
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A 15 ‑year follow ‑up of 195 patients with at least 
one severe hypoglycemic episode revealed an in‑
crease in the risk of coronary heart disease by 
10.8% and mortality by 28.3% as early as 3 years 
after the episode.46 The prospective study includ‑
ed 1209 patients with diagnosed diabetes from 
the Artherosclerosis Risk in Communities moni‑
tored in the years 1996–2003. The hypoglycemic 
episode was not associated with heart failure, 
atrial fibrillation, or stroke. However, severe hy‑
poglycemia increased the incidence of coronary 
heart disease by about 2 times, all ‑cause mortal‑
ity by about 1.7 times, and cancer mortality by 
about 2.5 times.
Recently, another analysis of data from 
the DCCT study was published, enriched with 
the results of coronary artery calcification assess‑
ments by computed tomography.47 The effect of 
hypoglycemia on coronary artery calcification in 
patient cohorts depending on the degree of gly‑
cemic control (HbA1c <7.5% vs HbA1c ≥7.5%) was 
assessed. In the group of patients with good gly‑
cemic control (HbA1c <7.5%), regression of ath‑
erosclerotic lesions was observed, whereas pro‑
gression of such lesions was observed in the group 
with uncontrolled glycemia. Moreover, there was 
a positive relationship between the incidence of 
hypoglycemic episodes and the degree of coro‑
nary artery calcification, particularly visible in 
the group with good glycemic control. The epi‑
sodes of hypoglycemia in a group with good gly‑
cemic control had a greater impact on the pro‑
gression of atherosclerosis than the lack of gly‑
cemic control.
The above studies allow to conclude that in 
order to achieve the therapeutic goals (glycemic 
control), the risk of hypoglycemia should be con‑
sidered and the treatment should be individual‑
ized. This task is particularly difficult in patients 
requiring insulin treatment, with T2DM, often 
with a high CV risk, who are most at risk of com‑
plications and increased mortality associated with 
hypoglycemia. Therefore, therapeutic strategies 
that generate the lowest incidence of hypogly‑
cemia should be used in this group of patients. 
The strategies should focus not only on proper 
insulin regimens and technical innovations, but 
also on patient education and empowerment.37
Long ‑acting insulin analogues have been shown 
to reduce the risk of hypoglycemia in patients 
with diabetes. One of the newest analogs is de‑
gludec, an ultra ‑long ‑acting basal insulin, recent‑
ly assessed in the DEVOTE study on CV safety. 
A total of 7637 patients with T2DM and high risk 
of CV events received either degludec or glargine 
(another long ‑acting insulin analog) once daily in 
addition to standard care.48 It was shown that de‑
gludec decreased the rate of severe hypoglycemic 
episodes by 40% and nocturnal severe hypoglyce‑
mic episodes by 53% compared with glargine, with 
a trend towards better CV effectiveness profile.
The authors suggested that the improved phar‑
macodynamic profile of degludec might provide 
better and safer glycemic control.
observed for 6% of the total CGM recording time 
and most frequently at night. Importantly, dur‑
ing the hypoglycemic states, mostly asymptom‑
atic, any changes in the electrocardiogram—bra‑
dycardia and atrioventricular blocks—were reg‑
istered in these patients.
More frequent application of CGM in patients 
with T2DM attracted attention to the detrimental 
role of hypoglycemia in patients treated with old‑
‑generation antidiabetic drugs. Recently, 30 pa‑
tients with T2DM treated with sulfonylurea 
(HbA1c, 6.9%) were subjected to 48 ‑hour CGM 
and electrocardiography with ventricular repolar‑
ization (QTc) and QT dynamicity analysis.42 Epi‑
sodes of hypoglycemia were identified in 30% of 
patients, mostly at night (67%) and with asymp‑
tomatic course (73%). QTc prolongation and high‑
er QT dynamicity were detected in 70% of hypo‑
glycemic patients. In these patients, QT abnor‑
malities persisted despite normalization of gly‑
cemia, suggesting that sulfonylurea ‑related hy‑
poglycemia may contribute to CV complications.
Large studies have compellingly shown that hy‑
poglycemia is a frequent phenomenon in diabetic 
patients during hypoglycemic therapy, particularly 
with the use of insulin. The incidence of hypogly‑
cemia and the relationship between hypoglycemia 
and CV risk in diabetic patients were analyzed by 
Khunti et al,43 using the data from the English Clin‑
ical Practice Research Datalink registry. The analy‑
sis included 265 867 patients with type 1 diabetes 
(T1DM; n = 3260) or T2DM (n = 10 422) diabetes, 
aged 30 years or older, and treated with insulin. 
Episodes of hypoglycemia were observed in 17.6% 
and 14% of patients with T1DM and T2DM, respec‑
tively. Among patients with no history of CVD, hy‑
poglycemic episodes were associated with the in‑
creased risk of CV events: by 92% and 50% in pa‑
tients with T1DM and T2DM, respectively. Even 
higher (2.5 ‑fold) CV risk was observed in patients 
with T2DM and CVD. What is more, it has been 
shown that the risk of CV events persists for a long 
time. The median time from the onset of the first 
hypoglycemic episode to the first CV event was 
1.5 years in both groups of patients.
A random ‑effects meta ‑analysis of hypoglyce‑
mia and CVD risk was performed in 10 studies: 
ADVANCE, VADT, ORIGIN, and others.44 The in‑
cidence of hypoglycemia ranged from 2% to 14%, 
depending on the study. The authors found that 
severe hypoglycemia was associated with an ap‑
proximately 2 ‑fold increased risk of CVD in pa‑
tients with T2DM.
Another observational study, conducted by 
Elwen et al,45 focused on the long ‑term follow‑
‑up of patients who had an episode of severe hy‑
poglycemia and required immediate medical at‑
tention. In total, 1835 episodes of hypoglycemia 
in 1156 patients were analyzed (the share of pa‑
tients with T1DM and T2DM was comparable: 
45% and 44%, respectively). The annual mortal‑
ity rate after a hypoglycemic episode was 4.45% 
in patients with T1DM and as high as 22.1% in 
patients with T2DM.
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a treatment strategy based on intensive glycemic 
control with new ‑generation antidiabetic drugs 
should benefit patients with T2DM.
New mechanisms of action and effectiveness of anti-
diabetic drugs Currently, the 2 most promising 
directions of clinical intervention are modula‑
tion of the incretin system and inhibition of sodi‑
um–glucose cotransporter 2 (SGLT2). In the con‑
text of improvement of prognosis in patients with 
T2DM with high CV risk, much interest has been 
stirred by the positive results of several recent 
studies assessing the safety and efficacy of drugs 
based on these mechanisms (liraglutide, semaglu‑
tide and empagliflozin, and canagliflozin), with 
a hard endpoint involving serious CV events, so 
called 3 ‑point MACE: composite of CV death, 
nonfatal MI, and nonfatal stroke.51-54 A summa‑
ry of CV outcomes observed for various antidia‑
betic drugs is presented in TABLE 1.
The main therapeutic targets of the incretin 
system are the intestinal glucagon ‑like peptide 
1 (GLP ‑1) and the enzyme dipeptidyl peptidase 
4 (DPP ‑4) that rapidly inactivates GLP ‑1. Incre‑
tin hormones play an important role in metab‑
olism, including stimulation of insulin release, 
suppression of glucagon secretion, delayed gas‑
tric emptying after food intake, and satiety. For 
the treatment of T2DM, 2 classes of medications 
that enhance incretin action are used: GLP ‑1 re‑
ceptor agonists (administered subcutaneously) 
and DPP ‑4 inhibitors (oral drugs). Both GLP ‑1 re‑
ceptor agonists and DPP ‑4 inhibitors have been 
investigated in CV studies in patients with T2DM. 
The potential role of GLP ‑1 in modifying CV risk 
through a potent glucose ‑lowering effect accom‑
panied with direct and indirect actions in specific 
A summary of the mechanisms underlying the 
effects of glycemic disturbances on the CV system 
is presented in FIGURE 1.
Does glycemic control prolong life? Recently, 
the results of a meta ‑analysis assessing the effect 
of intensive glycemic control (alone or as a com‑
ponent of multifactorial treatment) on the risk 
of nonfatal MI, nonfatal stroke, CV death, and 
death from any cause in patients with T2DM, were 
published.49 The analysis of 19 randomized clini‑
cal trials, including over 84 000 patients, showed 
that intensive glycemic control (as part of multi‑
factorial therapy) is associated with a reduction 
in the risk of MI, but no reduction (or increase) 
in incidence of stroke, CV deaths, or total mortal‑
ity, as compared with standard therapy.
The lack of a clear effect of intensive glycemic 
control on the prognosis of patients with dia‑
betes raised doubts as to whether the relation‑
ship between glycemia and CV risk, often demon‑
strated in large prospective observational studies, 
has a causal nature. One of the studies proving 
the existence of such a relationship is the analy‑
sis recently made by Ross et al,50 who used Men‑
delian randomization, using polymorphic vari‑
ants of genes previously associated with dysgly‑
cemia and diabetes, to assess the consequenc‑
es of exposure to lifelong glycemic disorders, re‑
gardless of other factors and without distortion 
by inverse relationships. The results of this anal‑
ysis clearly showed that abnormal fasting glucose 
insignificantly determined the risk of coronary 
heart disease, while the increased HbA1c values 
and the presence of diabetes are independent fac‑
tors increasing this risk. The results of this analy‑
sis gave hope that, in the long ‑term perspective, 
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outcome studies examining the safety of GLP‑
‑1 agonists, such as lixisenatide (ELIXA), exena‑
tide (FREEDOM ‑CVO), liraglutide (LEADER), and 
semaglutide (SUSTAIN ‑6) have been performed 
tissues and cell types was shown, for example, 
heart (increased cardioprotection), blood vessels 
(reduced blood pressure), fat, other tissues (re‑
duced inflammation), and others.55 At least 4 CV 
TABLE 1 Cardiovascular effects of antidiabetic agents reported in medical experiments and clinical trials
Trial name / 
Authors
Therapeutic target Tested drug Type of 
diabetes
No. of 
participants
Follow ­up 
duration
Primary 
endpoint
CV outcomes in 
drug ­treated 
group vs placebo
Ceriello et al23 Insulin receptors Insulin aspart 
(insulin analogue)
T2DM 33 6 hours NA Improved 
endothelial 
function
Von Birba et 
al24
Insulin receptors Insulin aspart and 
insulin detemir or 
regular insulin 
and NPH
T2DM 109 3 years Change of 
postprandial 
plasma 
glucose from 
baseline to 
the end of 
study 
at 36 months
Reduction in 
diastolic 
dysfunction
STOP ­NIDDM25 Competitive 
inhibitor of 
intestinal 
α ­glucosidases
Acarbose (a drug 
reducing 
postprandial 
hyperglycemia)
IGT 1429 3.3 years 
(mean)
Development
of diabetes
Reduction in:  
– risk of CV 
events by 49% 
– incidence of 
new cases of 
hypertension by 
34%
DEVOTE48 Insulin receptors Degludec (ultra­
­long ­acting basal 
insulin)
T2DM 7637 2 years 
(median)
3 ­point MACE No significant 
reduction in 
the risk of MACE 
(HR, 0.91; 95% CI, 
0.78–1.06)
Reduction in severe 
hypoglycemia 
episodes by 40%
LEADER51 GLP ­1 receptor Liraglutide (GLP­
­1 receptor 
agonist)
T2DM 9340 3.8 years 
(median)
3 ­point MACE Reduction in:  
– risk of MACE by 
13% 
– risk of CV death 
by 22%
SUSTAIN ­652 GLP ­1 receptor Semaglutide (GLP­
­1 receptor 
agonist)
T2DM 3297 2.1 years 
(mean)
3 ­point MACE Reduction in:  
– risk of MACE by 
26% 
– rate of nonfatal 
stroke by 39%
SAVOR ­TIMI 53;
EXAMINE;
TECOS56
DPP ­4 Saxagliptin, 
alogliptin, 
sitagliptin (DPP­
­4 inhibitors)
T2DM 16 492;
5380;
14 735
At least 
24 weeks
3 ­point MACE Neutral effect on 
primary MACE 
outcome in 
EXAMINE and 
TECOS
Higher rate of HF in 
SAVOR ­TIMI 53
EMPA ­REG53 SGLT2 Empagliflozin
(SGLT2 inhibitor)
T2DM 7020 3.1 years 
(median)
3 ­point MACE Reduction in: 
– risk of MACE by 
14% 
– risk of CV death 
by 38% 
– risk of 
hospitalization for 
HF by 35%
CANVAS54,58 SGLT2 Canagliflozin
(SGLT2 inhibitor)
T2DM 10 142 188.2 
weeks 
(mean)
3 ­point MACE Reduction in: 
– risk of MACE by 
14% 
– risk of 
hospitalization for 
HF by 33%
Abbreviations: CI, confidence interval; DPP ­4, dipeptidyl peptidase 4; GLP ­1, glucagon ­like peptide 1; HF, heart failure; HR, hazard ratio; IGT, impaired 
glucose tolerance; MACE, a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke; NA, not applicable; 
SGLT, sodium–glucose cotransporter 2; T2DM, type 2 diabetes mellitus
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protein responsible for the reabsorption of most 
filtered glucose in the kidney. Inhibition of SGLT2, 
besides lowering blood glucose levels, leads to sev‑
eral metabolic effects, such as improvements in 
insulin sensitivity, reduced glucose toxicity, and 
weight loss, as well as nonglycemic effects, such 
as blood pressure lowering and nephroprotec‑
tion.57 Numerous phase 2 and 3 clinical trials have 
been conducted to assess the benefits and risks of 
SGLT2 inhibitors, including CV effects. The results 
of 2 trials (EMPA ‑REG and CANVAS), described 
below, deserve attention due to their impact on 
mortality and heart failure hospitalization.
The EMPA ‑REG study53 was a multicenter, 
long ‑term, randomized, double ‑blind, placebo‑
‑controlled trial evaluating the safety of empa‑
gliflozin added to standard treatment in a group 
of 7020 patients with T2DM with high CV risk. 
Empagliflozin is an SGLT2 inhibitor that acts by 
blocking the reabsorption of glucose in the kid‑
neys, which leads to its elimination in the urine 
and lowering of its concentration in the blood. 
In more than 3 years of follow ‑up, the empa‑
gliflozin group had a 14% reduction in the risk of 
MACE events compared with placebo. There were 
no significant differences in the incidence of MI 
or stroke, but the empagliflozin group showed 
a 38% reduction in the risk of CV death, a 35% 
reduction in the risk of hospitalization for heart 
failure, and a 32% reduction in death risk for 
any reason. It is noteworthy that the frequen‑
cy of hypoglycemic episodes was comparable 
in both groups. In addition, there was a signif‑
icant body mass reduction (by 1.4 kg) in the em‑
pagliflozin group.
The same beneficial effect on body weight, as 
well as on glycated hemoglobin and blood pres‑
sure, was observed in patients treated with cana‑
gliflozin, an SGLT2 inhibitor, in the CANVAS 
study.58 A total of 10 142 patients with T2DM 
and high CV risk were assessed in a multicenter, 
double ‑blind, randomized, placebo ‑controlled tri‑
al for a mean duration of 188.2 weeks. The rate 
of MACE occurrence was significantly lower in 
the canagliflozin ‑treated group (by 14%) com‑
pared with placebo, although without mortality 
benefit. The MACE rate was higher in patients 
with T2DM with a prior CV event compared 
with those without a history of CVD (36.9 vs 
15.7/1000 patient ‑years, P <0.001).54 Addition‑
ally, hospitalized heart failure was reduced by 
33%. Safety data revealed a 2 ‑fold increase in 
the risk of amputation in a group receiving cana‑
gliflozin versus placebo.
There are also attempts to investigate new 
therapies as an additional benefit on top of op‑
timal medical care. Cardioprotective effects of 
omega ‑3 polyunsaturated fatty acids (n ‑3 PUFAs) 
at a dose of 2 g have been studied in patients with 
T2DM.59 The results showed no improvement in 
the metabolic status, including lipid control, insu‑
lin sensitivity, and adipokine profile, in patients 
treated with high doses of n ‑3 PUFAs and re‑
ceiving optimal medications for T2DM and CVD. 
in patients on a variety of approved antidiabet‑
ic therapies. The latter 2 trials yielded particular‑
ly interesting results, which are described below.
The LEADER trial51 evaluated the safety of lira‑
glutide (a GLP ‑1 receptor agonist) added to stan‑
dard treatment compared with placebo in a group 
of 9340 patients with T2DM and high CV risk. In 
the 3 ‑year follow ‑up period (median, 3.8 years), 
a 13% reduction in the risk of a composite prima‑
ry endpoint—MACE—was found in the liraglu‑
tide group. Compared with placebo, the liraglu‑
tide group showed a 22% reduction in the risk of 
CV death and a 15% reduction in the risk of death 
from any cause. There was a trend towards a low‑
er incidence of MI, stroke, and hospitalization for 
heart failure in the liraglutide group, although 
the differences between the groups were not sig‑
nificant. Moreover, a 22% reduction in the risk 
of nephropathy and a reduction in body weight 
(by 2.3 kg) was found in the liraglutide group. In 
addition to the significantly reduced mortality 
risk, there was a 31% reduction in the incidence 
of severe hypoglycemic episodes and a 20% re‑
duction in the overall incidence of hypoglycemia 
(severe and confirmed) in the liraglutide group, 
compared with placebo.
The results of a recently published SUSTAIN ‑6 
study with semaglutide, another GLP ‑1 agonist, 
are also promising. Semaglutide is a GLP ‑1 ana‑
logue with an extended half ‑life of approximate‑
ly 1 week allowing for once weekly subcutane‑
ous administration. The CV effects of semaglu‑
tide were investigated in a multicenter, random‑
ized, double ‑blind, placebo ‑controlled, parallel‑
‑group trial in 3297 patients with T2DM and 
high CV risk.52 A follow ‑up of 27 months (me‑
dian, 2.1 years) revealed a significant reduction 
in the risk of the primary composite MACE out‑
come (26%) in semaglutide ‑treated patients de‑
termined mainly by a significant decrease in 
the rate of nonfatal stroke (39%) and a nonsig‑
nificant decrease in nonfatal MI (26%), compared 
with the placebo group. However, no significant 
reduction in the rate of death from CV causes 
was found. Additional clinical effects were ob‑
served in patients receiving semaglutide, name‑
ly, sustained reduction in glycated hemoglobin 
levels, systolic blood pressure (SBP), and body 
weight, which are postulated as contributors o 
lowering CV risk.
The second target of incretin system is DPP ‑4, 
a key determinant of incretin bioactivity. The re‑
sults of the first 3 large randomized clinical trials 
on CV safety of DPP ‑4 inhibitors, namely, saxa‑
gliptin (SAVOR ‑TIMI 53), alogliptin (EXAMINE), 
and sitagliptin (TECOS), showed a neutral ef‑
fect on the primary MACE outcome. Moreover, 
the SAVOR ‑TIMI 53 study56 revealed a significant‑
ly higher rate of heart failure requiring admission 
to the hospital in the DPP ‑4 inhibitor–treated 
group versus the placebo group.
Gliflozins are a relatively new class of anti‑
hyperglycemic agents—inhibitors of SGLT2. 
SGLT2 is a sodium ‑dependent glucose transport 
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